News stories about Cerus (NASDAQ:CERS) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerus earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.51848019871 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Mid-Morning Market Update: Markets Open Higher; Boeing Beats Q4 Estimates (nasdaq.com)
- Mid-Day Market Update: Cascadian Therapeutics Jumps Following Acquisition News; Bellicum Pharmaceuticals Shares Plunge (nasdaq.com)
- Cerus Announces Public Offering of Common Stock (finance.yahoo.com)
- Cerus Announces Pricing of Public Offering of Common Stock (finance.yahoo.com)
- Cerus (CERS) Downgraded to “Sell” at Zacks Investment Research (americanbankingnews.com)
CERS has been the subject of several research analyst reports. Zacks Investment Research raised shares of Cerus from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Wednesday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $5.00 price objective on shares of Cerus in a research report on Friday, January 5th. Cowen set a $6.00 price objective on shares of Cerus and gave the company a “buy” rating in a research report on Thursday, October 5th. BidaskClub raised shares of Cerus from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Cerus in a research report on Friday, December 8th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $5.83.
Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. The company had revenue of $10.80 million during the quarter, compared to analyst estimates of $11.95 million. During the same period last year, the firm posted ($0.14) EPS. Cerus’s revenue for the quarter was up 5.9% compared to the same quarter last year. research analysts anticipate that Cerus will post -0.58 earnings per share for the current fiscal year.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.